#1 Clinical Trials Search in Europe

Edotreotide

This article examines the use of edotreotide, a radioactive drug, in clinical trials for diagnosing and treating neuroendocrine tumors (NETs). Edotreotide binds to somatostatin receptors expressed by NETs, allowing for targeted imaging and therapy. We’ll look at several studies evaluating edotreotide’s effectiveness compared to standard treatments for different types of NETs.

Table of Contents

What is EDOTREOTIDE?

EDOTREOTIDE is a medication that belongs to a class of drugs called somatostatin analogs. It is also known by several other names, including:

  • 68Ga-DOTA-d-Phe1-Tyr3-octreotide
  • 68Ga-DOTATOC
  • Ga-68 DOTA0-Tyr3-octreotide
  • Gallium Ga 68-DOTATOC
These different names refer to the same medication, but they may be used in different contexts or by different researchers.[1]

How does EDOTREOTIDE work?

EDOTREOTIDE works by binding to special proteins called somatostatin receptors, which are found in high numbers on the surface of certain types of tumor cells. When EDOTREOTIDE is attached to a radioactive substance like Gallium-68 or Lutetium-177, it can be used for two main purposes: 1. Diagnosis and imaging: The radioactive EDOTREOTIDE can be detected by special cameras, allowing doctors to see where tumors are located in the body. This is called a PET/CT scan (Positron Emission Tomography/Computed Tomography).[1] 2. Treatment: When attached to a different radioactive substance (like Lutetium-177), EDOTREOTIDE can deliver targeted radiation therapy directly to tumor cells, helping to shrink or kill them. This treatment is known as Peptide Receptor Radionuclide Therapy (PRRT).[2]

What conditions does EDOTREOTIDE treat?

EDOTREOTIDE is primarily used to diagnose and treat neuroendocrine tumors (NETs). These are rare tumors that can develop in various parts of the body, but most commonly in the digestive system (gut) and pancreas. Specific conditions that EDOTREOTIDE may be used for include:

  • Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
  • Lung neuroendocrine tumors
  • Thymus neuroendocrine tumors
  • Pituitary tumors
  • Carcinoid tumors
In some cases, EDOTREOTIDE is also being studied for use in other types of cancers, such as certain lymphomas.[3][4][5]

How is EDOTREOTIDE administered?

The administration of EDOTREOTIDE depends on whether it’s being used for diagnosis or treatment: 1. For diagnosis (imaging): EDOTREOTIDE is typically given as a single intravenous (IV) injection. After about an hour, the patient undergoes a PET/CT scan that lasts about 30-60 minutes.[1] 2. For treatment (PRRT): EDOTREOTIDE is usually given as an IV infusion every 6-8 weeks, for a total of 3-4 treatments. Each treatment session may last several hours, and patients often receive additional medications to protect their kidneys and prevent nausea.[2]

EDOTREOTIDE in Clinical Trials

EDOTREOTIDE is being studied in several clinical trials to better understand its effectiveness and safety. Some key areas of research include: 1. Comparing EDOTREOTIDE to other treatments: Researchers are studying how well EDOTREOTIDE works compared to other medications like everolimus for treating advanced neuroendocrine tumors.[2] 2. Improving diagnosis: Studies are looking at how EDOTREOTIDE PET/CT scans compare to traditional imaging methods like CT or MRI for detecting neuroendocrine tumors.[6] 3. Expanding use to other cancers: Some trials are exploring whether EDOTREOTIDE could be useful in treating other types of cancers, such as certain lymphomas.[3] 4. Optimizing treatment: Researchers are working to determine the best doses and treatment schedules for EDOTREOTIDE therapy.[4]

Potential Side Effects

While EDOTREOTIDE is generally well-tolerated, it can cause some side effects. When used for imaging, side effects are usually minimal. For treatment (PRRT), potential side effects may include:

  • Nausea and vomiting
  • Fatigue
  • Decreased blood cell counts
  • Kidney problems
It’s important to note that the exact nature and frequency of side effects are still being studied in clinical trials. Patients should discuss potential risks and benefits with their healthcare provider.[2]

Aspect Details
Drug Name Edotreotide (also known as DOTATOC when labeled with different isotopes)
Primary Uses Diagnostic imaging (Ga-68 DOTATOC), Targeted radiation therapy (Lu-177 edotreotide)
Target Conditions Neuroendocrine tumors (NETs) of various origins: gastroenteropancreatic, lung, thymus, pituitary
Mechanism of Action Binds to somatostatin receptors overexpressed on NET cells
Key Trials LEVEL trial (NCT05918302), NCT03049189
Comparator Treatments Everolimus, conventional imaging (CT, MRI)
Primary Outcomes Progression-free survival, overall response rate, diagnostic accuracy
Secondary Outcomes Overall survival, quality of life, toxicity evaluation
Administration Intravenous injection, multiple cycles for therapy
Safety Monitoring Acute and long-term toxicity evaluation

FAQ

  • What is edotreotide used for in clinical trials? Edotreotide is being studied for both diagnostic imaging and treatment of neuroendocrine tumors. When labeled with gallium-68, it's used in PET scans to detect tumors. When labeled with lutetium-177, it's used as a targeted radiation therapy.
  • How does edotreotide work? Edotreotide is a somatostatin analog that binds to somatostatin receptors, which are often overexpressed on neuroendocrine tumor cells. This allows it to target these tumors for imaging or delivering radiation therapy directly to the cancer cells.
  • What types of neuroendocrine tumors are being studied? The clinical trials are examining edotreotide's use in various NET types, including gastroenteropancreatic NETs, lung NETs, thymic NETs, and pituitary tumors.
  • How is edotreotide compared to current treatments? Several trials are comparing edotreotide-based therapies to standard treatments like everolimus. They're looking at outcomes such as progression-free survival, overall survival, and quality of life to determine if edotreotide offers benefits over current options.
  • Are there any side effects of edotreotide? The trials are monitoring for both acute and long-term side effects of edotreotide. As a targeted therapy, it may have fewer side effects than traditional chemotherapy, but potential risks are still being evaluated in these studies.

Ongoing Clinical Trials on Edotreotide

  • Study of Intra-Arterial Infusion of Lutetium (177Lu) Oxodotreotide for Adults with Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases

    Recruiting

    2 1 1 1
    Investigated drugs:
    France

  • Study on Edotreotide for Detecting Somatostatin Receptors in Patients with Metastatic Breast Cancer

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of Lutetium (177Lu) Oxodotreotide for Children with Relapsed or Refractory High-Risk Neuroblastoma

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark Lithuania The Netherlands Norway Spain Sweden

  • Evaluation of V-Cu64 versus V-Ga68 PET-CT imaging in adults with diagnosed or suspected neuroendocrine tumors

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    Poland

  • 68Ga-DOTATATE PET/CT Prognostic Assessment in Patients with Well-Differentiated Grade 2 Gastroenteropancreatic Neuroendocrine Tumors Treated with 177Lu-oxodotreotide and Edotreotide

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Edotreotide: A somatostatin analog drug that can be labeled with radioactive isotopes for use in diagnostic imaging or targeted radiation therapy of neuroendocrine tumors.
  • Neuroendocrine tumor (NET): A type of tumor that forms from cells that release hormones in response to signals from the nervous system.
  • Somatostatin receptor: A protein on cell surfaces that binds to somatostatin and related molecules. Often overexpressed on neuroendocrine tumor cells.
  • PET scan: Positron Emission Tomography, an imaging technique that uses radioactive tracers to visualize metabolic processes in the body.
  • Lutetium-177: A radioactive isotope of lutetium used in targeted radiation therapy when attached to molecules like edotreotide.
  • Gallium-68: A radioactive isotope of gallium used in PET imaging when attached to molecules like edotreotide.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives without the disease getting worse.
  • Overall survival (OS): The length of time from the start of treatment that patients are still alive.
  • Everolimus: A standard treatment drug for some types of neuroendocrine tumors, used as a comparison in some edotreotide trials.
  • RECIST criteria: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.

References

  1. https://clinicaltrials.gov/study/NCT03001349
  2. https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-177lu-edotreotide-and-everolimus-for-patients-with-inoperable-neuroendocrine-tumors-of-the-gastroenteric-or-pancreatic-origin/
  3. https://clinicaltrials.gov/study/NCT02488512
  4. https://clinicaltrials.gov/study/NCT05918302
  5. https://clinicaltrials.gov/study/NCT02419664
  6. https://clinicaltrials.gov/study/NCT03136328